For decades, hematopoietic stem cell transplantation (HSCT) has been one of the most successful cell therapies in medicine, with more than 40,000 transplants performed worldwide each year. Yet the field has a stubborn problem: not every patient who needs a transplant can get one. Ex vivo hematopoietic stem cell (HSC) expansion was designed to solve it, but progress has been slow. Only a handful of companies have pursued the approach, including Gamida Cell in Israel, ExCellThera in Canada, and Plasticell in the United Kingdom.
Now a Tokyo-based startup, Celaid Therapeutics, is emerging as a new contender.
The Problem Ex Vivo Expansion Aims to Solve
Cord blood is an attractive graft source. It is non-controversial, it can be banked without risk to the donor, and it requires only partial tissue matching rather than the full match demanded by bone marrow or peripheral blood. The limitation is cell dose. A single cord blood unit contains too few stem cells for most adults and adolescents, and low doses are linked to delayed engraftment, which raises morbidity and mortality.
When we interviewed Dr. Yael Margolin of Gamida Cell a few years ago, she described the scale of the unmet need. Of roughly 70,000 patients each year who are indicated for an allogeneic transplant, about half never receive one. Finding a matched unrelated donor can take three to four months, a delay during which disease may progress. Expanding cord blood ex vivo could make a transplant available to nearly every patient.
A Small Field Reaches Its First Approvals
Expansion is technically difficult because cultured stem cells tend to lose their functionality as they multiply. Few approaches have preserved potency at a scale and cost suitable for commercialization, but the field is now producing results.
Gamida Cell, with its nicotinamide (NAM) platform, won FDA approval for Omisirge in April 2023, the first expanded cord blood product to reach the market. The company has since been taken private and is now a subsidiary of the London-based firm Ayrmid. Omisirge has also received a second FDA approval, for severe aplastic anemia.
In Europe, Montreal-based ExCellThera has received conditional authorization from the European Commission for Zemcelpro, a cell therapy built on its UM171 small-molecule platform.
Plasticell, a UK developer using a different small-molecule method, announced a clinical partnership with Anthony Nolan in 2017.
Together, these companies have validated the concept. However, the field is still thin and the pediatric non-malignant space remains largely open.
Celaid Enters with Momentum
Celaid Therapeutics, which originated at the University of Tokyo and the University of Tsukuba, has developed proprietary technology for the selective ex vivo expansion of HSCs. Its lead program, CLD-001, is an expanded cord blood product for severe pediatric non-malignant diseases, including primary immunodeficiency, inherited metabolic disorders, aplastic anemia, and sickle cell disease. By overcoming the cell dose limitation, CLD-001 would also allow clinicians to choose cord blood units with better HLA matching, which Celaid hopes will reduce graft failure, transplant-related mortality, and graft-versus-host disease.
The company has reported positive nonclinical data, established its manufacturing process and transferred it to a U.S. contract development and manufacturing organization, and completed a Pre-IND meeting with the FDA. A first-in-human trial in the U.S. is now the next step.
Why the Raise Matters
On October 4, 2026, Celaid announced the second close of its Series B round, raising JPY 400 million (about USD $2.6 million) from Shionogi & Co. and Teikoku Ventures. The amount is modest by biotech standards, but the investors are notable. Shionogi is a major Japanese pharmaceutical company, and Teikoku Ventures is the corporate venture arm of the Teikoku Seiyaku Group. Their participation signals that pharma is taking an interest in HSC expansion and placing some strategic bets on it.
Shionogi’s reasoning speaks directly to the unmet need. Keisuke Kusumoto, Director and Head of CVC at Shionogi, noted that while transplantation can offer “the only curative treatment option for certain serious hematologic and inherited diseases,” challenges such as donor shortages and post-transplant complications remain. “We believe Celaid’s hematopoietic stem cell expansion technology represents an innovative approach with the potential to overcome these challenges and provide treatment opportunities to more patients,” he said.
Teikoku Ventures looked further ahead, pointing to the technology’s potential as a foundational platform for ex vivo HSC gene therapies, an area of growing commercial importance.
Celaid also advanced to Stage 3 of Japan’s AMED startup ecosystem program, bringing cumulative funding, including grants, to about JPY 3.42 billion (USD 22.1 million).
The Road Ahead for Celaid Therapeutics
Celaid’s funding is small next to the capital needed for late-stage development, and the company will need substantially more to run clinical trials. Still, with strategic pharma backing, FDA engagement, and a U.S. manufacturing partner in place, Celaid is a company to watch. With the first expanded products now approved, ex vivo expansion is no longer a theory. The next question is who can extend its benefits to the patients, particularly children, who still have no transplant option.
You can read Celaid’s full release here.
